Aldesleukin

Definition

A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.

Also known as 125-L-Serine-2-133-interleukin 2, ALDESLEUKIN, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2 — per NCIT

Also identified as

• ATC L03AC01 per RXNORM
• NCIT NCIT:C1498 per NCIT
• SCTID 108804009 per RXNORM
• SCTID 386917000 per RXNORM
• UNII M89N0Q7EQR per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.